Adamas Pharmaceuticals (ADMS) has taken numerous steps to proliferate GOCOVRI adoption and the numbers are slowly grinding higher. The company’s third-quarter product sales came in a $13.9M, which was a 9% increase over Q2 and a 31% increase over Q3 of last year. Thus far, GOCOVRI has recorded $38.3M in sales, which is up 85% compared to this point in 2018. There is evidence that progress is being made, and the company’s adjustments to their Parkinson’s commercial strategy should translate into shareholder value in the future. Now, investors should turn their attention back